Tralokinumab (Adtralza, Leo) 300 mg/2 mL is now available as a pre-filled pen in Canada.
A human, monoclonal antibody targeting the interleukin (IL)-13 cytokine, tralokinumab is currently indicated in patients 12 and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. It is marketed as Adbry in the U.S.
Prior to the introduction of the pre-filled pen, tralokinumab was only available in a 1 mL pre-filled syringe. With the new 2 mL pre-filled pen, patients now have another option with half the number of required injections compared to the 1 mL pre-filled syringe.
“The pre-filled pen simplifies the injection process and can be helpful for those who are uncomfortable with the sight of needles,” says Chih-ho Hong, MD, a dermatologist in Greater Vancouver, BC, and national coordinating investigator for ECZTRA 6 trial in Canada, in a news release. “It also means half the number of required injections. This option can help reduce patient treatment burden significantly.”
“Atopic dermatitis can be difficult to manage, and can feel overwhelming,” adds Amanda Cresswell-Melville, Executive Director, Eczema Society of Canada. “More treatment options mean more hope to those impacted by this burdensome condition.”
For patients who prefer the pre-filled syringe, this option will continue to be available in Canada.
